CRISPR THERAPEUTICS AG (CRSP) FY2026 Q2 P&L / Income Statement

CRISPR THERAPEUTICS AG (CRSP) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

10,181,000 US dollars

Total operating expenses

127,450,000 US dollars

Loss from operations

negative 117,269,000 US dollars

Total other income, net

27,075,000 US dollars

Net loss before income taxes

negative 90,194,000 US dollars

Provision for income taxes

960,000 US dollars

Net loss

negative 91,154,000 US dollars

Collaboration Revenue

10,000,000 US dollars

Grant Revenue

181,000 US dollars

Total operating expenses

127,450,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.